|
- Tirofiban Uses, Side Effects Warnings - Drugs. com
What is tirofiban? Tirofiban is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries)
- Tirofiban - Wikipedia
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication It belongs to a class of antiplatelets named glycoprotein IIb IIIa inhibitors
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4 5 hours after onset Vascular reocclusion may occur after intravenous thrombolysis and may be preventable wi
- Aggrastat (tirofiban) dosing, indications, interactions, adverse . . .
Medscape - Indication-specific dosing for Aggrastat (tirofiban), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost
- Tirofiban: Side Effects, Uses, Dosage, Interactions, Warnings
What Is Tirofiban and How Does It Work? Tirofiban is a prescription medication used to treat Non-ST Elevated Acute Coronary Syndrome (NSTE-ACS) Tirofiban is available under the following different brand names: Aggrastat
- Tirofiban (intravenous route) - Side effects uses
Tirofiban injection is used to prevent blood clots from forming in the arteries of the heart after certain types of chest pain and heart attacks It may also be used in patients who are having certain heart and blood vessel procedures Tirofiban is an antiplatelet medicine
- Tirofiban: Uses, Interactions, Mechanism of Action | DrugBank Online
Tirofiban is a platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery
- Evaluation of safety and efficacy of Tirofiban injection for treating . . .
Tirofiban combined with conventional treatment significantly improves neurological deficits and disease outcomes in AIS patients without increasing the risk of bleeding and mortality
|
|
|